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Abstract
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in
CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundrum. In our
study, the evidence of blood-brain barrier (BBB)-penetrating CAR T cells as a culprit was revealed. A patient with
acute lymphocytic leukemia developed sustained pyrexia with tremors about 6 h after CART19 infusion, followed by
a grade 2 cytokine release syndrome (CRS) and neurological symptoms in the next 3 days. Contrast-enhanced
magnetic resonance showed signs of intracranial edema. Lumbar puncture on day 5 showed an over 400-mmH2O
cerebrospinal pressure. The cerebrospinal fluid (CSF) contained 20 WBCs/μL with predominant CD3+ T cells. qPCR
analysis for CAR constructs showed 3,032,265 copies/μg DNA in CSF and 988,747 copies/μg DNA in blood. Cytokine
levels including IFN-γ and IL-6 in CSF were extremely higher than those in the serum. Methyprednisone was
administrated and the symptoms relieved gradually. The predominance of CART19 in CSF and the huge
discrepancies in cytokine distributions indicated the development of a cerebral CRS, presumably featured as CSF
cytokines largely in situ produced by BBB-penetrating CAR T cells. For the first time, we reported the development
of cerebral CRS triggered by BBB-penetrating CAR T cells.
Trial registration: ChiCTR-OCC-15007008.
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Chimeric antigen receptor-modified (CAR) T cells tar-
geting CD19 (CART19) have shown therapeutical activ-
ities in refractory/relapsed acute lymphocytic leukemia
(ALL) [1–4]. Neurologic complications were reported in
several trials [5–8]; however, the etiological nature still
remains a conundrum. In our recent CART19 clinical
trial (ChiCTR-OCC-15007008), the evidence of blood-
brain barrier (BBB)-penetrating CAR T cells as a culprit
was revealed.
An enrolled female patient of BCR/ABL p210(+)
refractory/relapsed ALL with previous recurrence of
central nervous system lymphoma (CNSL) was infused
with autologous CART19 after conditioning chemother-
apy with fludarabine and cyclophosphamide (detailed pa-
tient and methodological information was included in
Fig. 1a and Additional file 1). CART19 preparation and
infusion were described in Fig. 1b, c and Additional file
2 [8]. About 6 h after CART19 infusion, the patient
developed sustained pyrexia with tremors (Fig. 2a).
Three days later, the patient complained of headache,
vomit, and recurrent right-sided facial and limb paresis
with a homolateral blurred vision and defective visual
field. Physical examination showed decreased myodyna-
mia (grade 3), high blood pressure, and positive Babinski
and Kernig signs. Papilloedema was observed by oph-
thalmoscope. Contrast-enhanced magnetic resonance
imaging showed signs of intracranial edema (Fig. 2b).
Serum cytokines including INF-γ, IL-6, and IL-10
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elevated synchronously, supporting a grade 2 cytokine
release syndrome (CRS) (Fig. 2c). The cerebral symp-
toms were not relieved by a bolus infusion of manni-
tol. Lumbar puncture on day 5 showed an over 400-
mmH2O cerebrospinal pressure. The cerebrospinal
fluid (CSF) contained 20 WBCs/μL and 4.0 g/μL pro-
tein (Fig. 2d). CD3+ T cells were predominant in CSF,
with few CD19+ B cells (Fig. 2e) which excluded
CNSL. qPCR analysis for CAR construct showed
3,032,265 copies/μg DNA in CSF and 988,747 copies/
μg DNA in blood. Cytokine levels in CSF were
extremely higher than those in the serum, with IFN-γ
at 2977 versus 152 pg/ml and IL-6 at 8475 versus
46 pg/ml (Fig. 2c). Methyprednisone was adminis-
trated at 3 mg/kg/day since day 5, and the symptoms
relieved gradually. By day 9, all cerebral symptoms
and signs disappeared, and serum IFN-γ and IL-6
levels decreased to normal ranges. Then, methypred-
nisone was de-escalated and tapered on day 14. The
patient achieved complete remission (CR) with min-
imal residual disease (MRD) negative 10 days after
CART19 infusion.
Fig. 1 Efficacy of chemotherapy and CART19 therapy in the patient (female, 43 years old). a Trend in BCR-ABL/ABL ratio after chemotherapy
combined with tyrosine kinase inhibitor (TKI) treatment and CART therapy. The patient underwent courses of VDCLP (vincristine, daunomycin,
cyclophosphamide, asparaginase, and dexamethasone), hyper-CVAD part A (cyclophosphamide, vincristine, doxorubicin, and dexamethasone),
hyper-CVAD part B (methotrexate and cytosine arabinoside), IAE (idarubicin, cytosine arabinoside, and etoposide), MTX (methotrexate) + L-ASP
(L-asparaginase), IA (idarubicin and cytosine arabinoside), and EA (etoposide and cytosine arabinoside) + DXM (dexamethasone) chemotherapy.
Three times of the central nervous system lymphoma (CNSL) were also indicated. About 15 times of intrathecal chemotherapy with methotrexate,
cytosine arabinoside, and DXM without cranial irradiation were performed before CART19 infusion. Her cerebral spinal fluid (CSF) contained no
white blood cells (WBCs) and normal level of protein when she was recruited for the CART19 clinical trial. Before CART19 infusion, 10.7 % cells
remaining in the marrow were CD19+ leukemia cells, and BCR-ABL/ABL ratio in the marrow was 27 %. b Lentiviral vector applied to transfect T
lymphocytes from the patient. A pseudotyped clinical-grade lentiviral vector including anti-CD19 scFv derived from FMC63 murine monoclonal
antibody, human CD8α hinge, and transmembrane domain and human 4-1BB and CD3ζ-signaling domains was constructed. c Procedure of
CART19 manufacture and the clinical application scheme. Lymphocyte-depleting chemotherapy regimen FC consisted of FLU (fludarabine)
30 mg/m2 days 1 to 3 and CTX (cyclophosphamide) 750 mg/m2 day 3




Fig. 2 (See legend on next page.)
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In the current study, the patient had experienced
recurrent CNSL before CART19 infusion. Since CNS tis-
sues lack CD19 expression [9], the CNS complications
might less probably result from direct interactions be-
tween CD19+ cells and CART19. The predominance of
CART19 in CSF and the huge discrepancies in inflam-
matory cytokine distributions strongly indicated the de-
velopment of a cerebral CRS, presumably featured as
CSF cytokines largely in situ produced by BBB-
penetrating CAR T cells. Although no evidence of WBCs
in CSF was observed before CART19 infusion, potent
minimal residual CD19+ leukemia cells less than detec-
tion limits might enter CNS [10] and dramatically trig-
ger activation of CAR T cells. Notably, this patient
complicated severe cerebral CRS rather than systemic
compromisations, suggesting that systemic and cerebral
CRS were independent processes.
We have to acknowledge the comprehensive roles of
CRS in CAR T cell therapy. Theoretically, cerebral CRS
might facilitate elimination of CNSL and also cause se-
vere CNS complications. Therefore, the timing and strat-
egy to terminate CRS should be deliberately evaluated in
clinical practice. Previous reports showed neurologic
toxicities were not prevented by cytokine blockade via
tocilizumab [6–8] due to its incapability of crossing the
BBB. Our experience of using glucocorticoid as a salvage
option could be instructive for a quick control of the se-
vere CRS.
In all, we reported for the first time the development
and control of cerebral CRS triggered by BBB-
penetrating CAR T cells. This study provided insights
into the etiology, diagnosis, and treatment of CRS after
CAR T cell therapy.
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Fig. 2 Predominant cerebral cytokine release syndrome (CRS) manifestations after CART19 therapy. a Wave changes in body temperature after
CART19 infusion, with a maximum temperature per 24-h period indicated by the squares. b Heterogeneous structures with punctiform nodal or
linear enhancement in the cerebellar sulcus and hidden parts (arrows) by contrast-enhanced MRI on day 5 after CART19 infusion, indicating the
local infiltration of inflammatory cells. c Inflammatory cytokine levels in peripheral serum and CSF, respectively, at different time points. CSF cytokine
concentrations were extremely higher than in the serum, with IFN-γ levels 20 times higher and IL-6 levels 190 times higher. d Mononuclear cell (MNC)
counts and protein levels in CSF and profiles of cerebrospinal pressure at different times of CNSL and cerebral CRS after CART19 infusion. As indicated,
the patient suffered three times of recurrent CNSL, with the highest MNC counts (300/μL) and protein levels (0.19 g/μL) in CSF and a
higher cerebrospinal pressure (265 mmH2O). During CRS, the CSF contained higher levels of protein (4.0 g/μL) and less amount of WBCs
(20/μL). e CSF cells were predominantly CD3+ T cells with few CD19+ B cells by FACS analysis which did not support a diagnosis of
CNSL. For leukoencephalopathy, MRI imaging usually discloses bilateral and symmetric white matter areas of hyperintense signal on T2-weighted and
fluid-attenuated inversion recovery images and signs of restricted diffusion; CSF usually contains a slight increase of WBC counts and protein levels.
Thus, leukoencephalopathy was not considered. Routine CSF cultivation and specific virus DNA detection excluded bacteria, virus, and fungal infection
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